Danaher Corporation $DHR Shares Purchased by Private Wealth Partners LLC

Private Wealth Partners LLC raised its holdings in Danaher Corporation (NYSE:DHR) by 6.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97,828 shares of the conglomerate’s stock after acquiring an additional 5,765 shares during the quarter. Danaher accounts for about 1.4% of Private Wealth Partners LLC’s portfolio, making the stock its 22nd biggest holding. Private Wealth Partners LLC’s holdings in Danaher were worth $19,395,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in DHR. Norges Bank bought a new stake in shares of Danaher during the 2nd quarter worth $1,979,503,000. Viking Global Investors LP lifted its holdings in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after purchasing an additional 2,455,994 shares during the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the period. Primecap Management Co. CA increased its stake in Danaher by 924.2% in the 2nd quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after purchasing an additional 1,118,318 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after buying an additional 788,499 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.4%

NYSE DHR opened at $218.82 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.10 and a debt-to-equity ratio of 0.35. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $242.80. The firm’s fifty day simple moving average is $230.60 and its 200-day simple moving average is $213.96. The company has a market capitalization of $154.56 billion, a PE ratio of 43.42, a price-to-earnings-growth ratio of 3.12 and a beta of 0.89.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. During the same quarter in the previous year, the company posted $2.14 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were paid a $0.32 dividend. The ex-dividend date was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is 25.40%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DHR. Morgan Stanley began coverage on shares of Danaher in a report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price for the company. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Evercore ISI restated an “outperform” rating and issued a $254.00 target price on shares of Danaher in a report on Wednesday. Finally, KeyCorp reiterated an “overweight” rating on shares of Danaher in a report on Thursday. Twenty research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.32.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,248 shares of company stock worth $6,609,663 over the last ninety days. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.